AJM1: A Protein Implicated in Alzheimer's Disease (G389813)

Target Name: AJM1

NCBI ID: G389813

AJM1

AJM1: A Protein Implicated in Alzheimer's Disease

AJM1, or alternating current machine one, is a protein that is expressed in the brain and has been shown to play a role in the development and progression of various neurological disorders, including Alzheimer's disease. The protein is made up of 128 amino acids and has a calculated molecular weight of 13.9 kDa.

One of the key functions of AJM1 is its role in the production of electrical signals in the brain. These signals, known as action potentials, are responsible for the rapid transmission of information between neurons and are essential for the function of the nervous system.

Research has shown that AJM1 is involved in the regulation of electrical activity in the brain and that its levels are altered in a variety of neurological disorders, including Alzheimer's disease.

One of the ways that AJM1 is linked to Alzheimer's disease is its role in the formation of neurofibrillary tangles, a hallmark of the disease that is characterized by the accumulation of toxic waste material in the brain. These tangles can cause the death of nerve cells and contribute to the decline in cognitive function that is characteristic of Alzheimer's disease.

Another way that AJM1 is associated with the development of Alzheimer's disease is its role in the regulation of the immune system. Studies have shown that AJM1 interacts with a protein called Tau and that this interaction may play a role in the development of the disease.

In addition to its role in the immune system, AJM1 has also been shown to be involved in the regulation of the blood-brain barrier, which is responsible for controlling the movement of substances into and out of the brain. This may be important for the development of neurodegenerative diseases because the barrier can become weakened and allow toxic substances to enter the brain.

The potential therapeutic benefits of AJM1 are significant. By targeting this protein, researchers may be able to develop new treatments for a variety of neurological disorders, including Alzheimer's disease. Additionally, by studying the role of AJM1 in the development and progression of disease, researchers may be able to gain insights into the underlying mechanisms of these disorders and develop new strategies for treatment.

Overall, AJM1 is a protein that has the potential to be a drug target or biomarker for a variety of neurological disorders, including Alzheimer's disease. Further research is needed to fully understand its role in these conditions and to develop effective treatments.

Protein Name: Apical Junction Component 1 Homolog

Functions: May be involved in the control of adherens junction integrity

The "AJM1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AJM1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets